We are among the elite 1% NCI-designated comprehensive cancer centers in the U.S. — and we are ranked in the top 1% of all U.S. hospitals for cancer care, according to U.S. News & World Report.
Video could not be played
Video could not be played
Cancer Clinical Trials
- Blood & Bone Marrow Cancers
- Brain, Spine & Central Nervous System Cancers
- Breast Cancer
- Childhood Cancers
- Endocrine System Cancers
- Gastrointestinal (GI) Cancers
- Genitourinary (GU) & Urologic Cancers
- Gynecologic Cancers
- Head & Neck Cancers
- Kaposi Sarcoma & AIDS-Related Cancers
- Lung & Chest Cancers
- Prostate Cancer
- Sarcomas
- Skin Cancer
Treating More Than 400 Types of Cancer
Over 500 Active Clinical Research Studies
Video could not be played
Navigating Your Cancer Care
At Montefiore Einstein Comprehensive Cancer Center, you receive evidence-based cancer care that addresses the unique needs of each individual patient. Our NCI-designated comprehensive cancer center brings the worlds of clinical care and academic research together and allows for the translation of novel, leading-edge scientific discoveries into improved clinical outcomes and new life-saving treatments.
Using a multidisciplinary team of disease-focused experts, our full-service cancer center is focused on the prevention, early diagnosis and treatment of cancer while incorporating a comprehensive spectrum of traditional and holistic care. This allows us to deliver highly specialized and coordinated compassionate care for the whole person, address complex medical needs and improve the quality of life for each and every patient.
Video could not be played
Over 50 Years of Cancer Research & Treatment Breakthroughs
Video could not be played
Our Latest News & Research
Advancing human health, scientific discovery and innovation through cancer research
Transforming Possibilities in Metastatic Lung Cancer
Metastatic lung cancer, particularly at Stage IV with the presence of a brain tumor, poses tough challenges. However, Victor Hunter’s journey illustrates how research is reshaping patient care at Montefiore Einstein. He participated in an innovative clinical trial led by Dr. Chandan Guha and his team, where a groundbreaking combination of targeted radiation and immune-stimulating injections took center stage.
Video could not be played
Leaders in the Science of Cancer Care
At Montefiore Einstein Comprehensive Cancer Center, we’re committed to finding new and better cancer treatment options.
Our research breakthroughs continue to lead to game-changing cancer treatment practices and give patients a chance to join upcoming clinical trials, which may offer potentially successful treatment options. We’ve received accreditation from the NCI for more than 50 years in a row. Our facility is one of only 56 NCI-designated comprehensive cancer centers across the United States, which means that through the NCI peer review process, we’ve been recognized by our national colleagues for the remarkable strengths of our exceptional science integrated with extraordinary multidisciplinary patient care. We’re also the only NCI-designated comprehensive cancer center located between Westchester and Buffalo. We made that expansion from Manhattan to Westchester to provide convenient access to cancer patients across the region.
Video could not be played
State-of-the-Art Technology
At Montefiore Einstein Comprehensive Cancer Center, we are proud to provide patients with the newest technology available and offer the latest surgical and therapeutic techniques. Our goal is to utilize the least invasive solutions for your cancer care.
That is why we offer the latest in image-guided, immuno-, cellular and targeted therapies, to name just a few.
Some of our other molecular imaging technology includes the latest three-dimensional systems for bioluminescence imaging (BLI), fluorescence molecular imaging (FMI), positron emission tomography (PET) and single-photon emission computed tomography (SPECT).
Committed to Moving Faster Than Cancer
Video could not be played
Cancer Center Highlights Report
Our Highlights Report documents our remarkable innovations in research, treatment and care.
-
$69M
in cancer-related research funding
-
1965
cancer patients enrolled in clinical research studies
-
200,000+
outpatient visits
-
700+
physicians, nurse practitioners, physician assistants, and allied health professionals
Video could not be played
Video could not be played
Video could not be played
Meet Your Cancer Care Team
Montefiore Einstein Comprehensive Cancer Center is home to 14 teams of award-winning, multidisciplinary experts who will develop a highly personalized treatment plan specific to your particular type of cancer, including those considered rare.
Events at Montefiore Einstein Comprehensive Cancer Center
At Montefiore Einstein Comprehensive Cancer Center, we’re passionate about enriching the health and well-being of our community. To meet different interests and needs, we offer in-person and virtual events, classes, support groups and other activities year-round.
Tuesday, November 10 from 12:00pm - 01:00pm
Forchheimer Medical Science Building
In person
Lung Cancer Awareness Month Event
Friday, November 13 from 11:30am - 05:00pm
Price Center/Block Research Pavillion - Lefrak Auditorium (Room 151)
Saturday, November 21 from 10:00am - 01:00pm
St. Jerome Hands Community Center
Wednesday, January 27 from 11:00am - 02:00pm
NYS Parks and Recreation
- Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
-
Start Date
December 6, 2023
-
Conditions
NON-SMALL CELL LUNG CANCER
- Phase 3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
-
Start Date
October 21, 2024
-
Conditions
CARCINOMA, NON-SMALL-CELL LUNG
- Phase 3
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
-
Start Date
April 9, 2026
-
Conditions
SOLID TUMORS
- Phase 2, Phase 3
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
-
Start Date
February 27, 2025
-
Conditions
PROSTATE CANCER
- Phase 1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
-
Start Date
December 20, 2023
-
Conditions
NEOPLASMS
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
-
Start Date
June 7, 2025
-
Conditions
PANCREATIC CANCER, PANCREATIC ADENOCARCINOMA, METASTATIC PANCREATIC CANCER
- Phase 3
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
-
Start Date
August 1, 2025
-
Conditions
ENDOMETRIAL CANCER, MALIGNANT SOLID TUMOUR
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
-
Start Date
February 13, 2025
-
Conditions
AIDS-RELATED DIFFUSE LARGE B-CELL LYMPHOMA, AIDS-RELATED NON-HODGKIN LYMPHOMA, HIV INFECTION, RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, RECURRENT GRADE 3B FOLLICULAR LYMPHOMA, RECURRENT HIGH GRADE B-CELL LYMPHOMA, RECURRENT NON-HODGKIN LYMPHOMA, RECURRENT PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, RECURRENT TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA, REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA, REFRACTORY HIGH GRADE B-CELL LYMPHOMA, REFRACTORY NON-HODGKIN LYMPHOMA, REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, REFRACTORY TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA
Video could not be played
Video could not be played
Video could not be played
Video could not be played
Video could not be played
Video could not be played
Video could not be played
Video could not be played
Video could not be played